REO-10: A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer

Clinical Cancer Research

Volumn 16, Issue 22, 2010, Pages 5564-5572

  Comins, Charles ^a   Spicer, James ^b   Protheroe, Andrew ^d   Roulstone, Victoria ^c   Twigger, Katie ^c   White, Christine M ^c   Vile, Richard ^e   Melcher, Alan ^f   Coffey, Matt C ^g   Mettinger, Karl L ^g   Nuovo, Gerard ^h   Cohn, David E ^h   Phelps, Mitch ^h   Harrington, Kevin J ^c   Pandha, Hardev S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g ONCOLYTICS BIOTECH INC   (Canada)

^h THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; REOLYSIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; HYPOKALEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PERIANAL ABSCESS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REOVIRUS; SIDE EFFECT; SOLID TUMOR; STOMACH HEMORRHAGE; TACHYCARDIA; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REOVIRIDAE; TAXOIDS;

EID: 78349299472     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1233     Document Type: Article

References (30)

1. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963;77:29-37.
2. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54:307-15.
3. Forsyth P, Roldan G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16:627-32.
4. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reovirus®, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-9.
5. Vidal LKV, Beirne D, Twigger K, et al. Phase I trial of intratumoral administration of reovirus type 3 with radiation in patients with advanced malignancies. J Clin Oncol 2007;25:14009.
6. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37.
7. Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14:259-69.
8. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62.
9. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007;15:1522-30.
10. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
11. Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) 2008;20:548-54.
12. Thirukkumaran CM, Nodwell MJ, Hirasawa K, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010;70:2435-44.
13. Pandha HS, Heinemann L, Simpson GR, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009;15:6158-66.
14. Sei S, Mussio JK, Yang QE, et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 2009;8:47.
15. Steele TA, Cox DC. Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Biother 1995;10:307-15.
16. Errington F, Steele L, Prestwich R, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180:6018-26.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15:911-20.
19. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
20. Angelova AL, Aprahamian M, Grekova SP, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009;15:511-9.
21. Petrowsky H, Roberts GD, Kooby DA, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001;75:7050-8.
22. Gutermann A, Mayer E, von Dehn-Rothfelser K, et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006;17:1241-53.
23. Pawlik TM, Nakamura H, Mullen JT, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002;95:1171-81.
24. Raki M, Kanerva A, Ristimaki A, et al. Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005;12:1198-205.
25. Tyminski E, Leroy S, Terada K, et al. Brain tumor oncolysis with replication- conditional herpes simplex virus type 1 expressing the pro-drug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005;65:6850-7.
26. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010;21:91-8.
27. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44.
28. Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995;31A Suppl 4:S21-4.
29. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14 Suppl 2:ii41-4.
30. Pivot X, Asmar L, Hortobagyi GN. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (review). Int J Oncol 1999;15:381-6.